“`html
Abu-Raddad LJ, et al. Global, regional, and national estimates of the burden of respiratory syncytial virus infection in young children: a modelling study. Lancet. 2021;398(10304):1289-1302.
Falsey AR,et al.RSV-associated hospitalization among adults aged 65 years and older. J Infect Dis.2005;192(11):1779-1784.
Glezen WP, et al. Respiratory syncytial virus disease in elderly and immunocompromised persons. J Infect Dis. 1986;153(6):941-948.
National Institute for Health and Care Excellence. Respiratory syncytial virus (RSV). https://www.nice.org.uk/guidance/ng188. Published 2021. Accessed 15 Jul 2024.
Centers for Disease Control and Prevention. RSV in Older Adults and immunocompromised Adults.https://www.cdc.gov/rsv/high-risk/older-adults.html. Accessed 15 Jul 2024.
European Medicines Agency. Beyfortus (nirsevimab). https://www.ema.europa.eu/en/medicines/human/medicines/beyfortus. Accessed 15 Jul 2024.
Pfizer. Pfizer Announces Completion of Regulatory Submissions for RSV Vaccine Candidate
